These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 37609730)

  • 1. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
    Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
    Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibitor: Introduction.
    Raychaudhuri SP; Raychaudhuri SK
    Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
    Ryguła I; Pikiewicz W; Kaminiów K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.
    Raychaudhuri SP; Shah RJ; Banerjee S; Raychaudhuri SK
    Curr Rheumatol Rep; 2024 Jun; 26(6):204-213. PubMed ID: 38492148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK inhibitors and autoimmune rheumatic diseases.
    Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
    Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [JAK inhibition in the treatment of inflammatory rheumatic diseases].
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
    O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
    Front Immunol; 2021; 12():672461. PubMed ID: 34248953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
    BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Janus kinase inhibitors for skin disorders].
    Solimani F; Ghoreschi K
    Dermatologie (Heidelb); 2024 Oct; 75(10):781-790. PubMed ID: 39212722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
    Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2017 Jul; 29(4):311-316. PubMed ID: 28394822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.